Team Approach for XELOX+Bevacizumab Therapy

概要

論文の詳細を見る
XELOX+Bevacizumab (BV) is one of the most common regimens for advanced colorectal cancer in Europe and the US, but there is little clinical data in Japan. We studied the effectiveness and safety of XELOX+BV therapy for advanced colorectal cancer patients in a phase II clinical trial. The primary endpoint was response rate (RR). Secondary endpoints were progression-free survival (PFS), time to treatment failure (TTF) and incidence of adverse events. In this study we used the team approach for management of adverse events. This report describes the effectiveness of adverse event management and the improvement of ingestion compliance by the team of doctors, nurses, and pharmacists. The rate of Hand Foot Syndrome grade 2/3 in a domestic phase I/II study JO19380 was 17.2%/1.7% respectively, while that in our study was 13.2%/0%. The relative dose intensity of six courses was 89.2% (L-OHP) and 91.0% (XELODA), respectively. The response rate was 66.7%, and the decrease control rate was 96.7%. Outpatient chemotherapy will increase gradually, and so it will become even more important to control adverse events at home.